SRD5A polymorphisms and biochemical failure after radical prostatectomy

European Urology

Volumn 60, Issue 6, 2011, Pages 1226-1234

  Audet Walsh, Etienne ^a   Bellemare, Judith ^a   Nadeau, Genevive ^a,b   Lacombe, Louis ^b   Fradet, Yves ^b   Fradet, Vincent ^b   Huang, Shu Pin ^c   Bao, Bo Ying ^d   Douville, Pierre ^b   Girard, Hugo ^a   Guillemette, Chantal ^a   Lévesque, Eric ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b Université Laval   (Canada)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

5 reductase; Biochemical recurrence; Germ line polymorphisms; Prostate cancer; SRD5A genes

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2;

ADULT; AGED; ARTICLE; ASIAN; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; COHORT ANALYSIS; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREATMENT OUTCOME;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; HAPLOTYPES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUEBEC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TREATMENT FAILURE;

EID: 80255138394     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.06.020     Document Type: Article

References (31)

1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M.J. Thun Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66 (Pubitemid 46148091)
2. H. Gronberg Prostate cancer epidemiology Lancet 361 2003 859 864 (Pubitemid 36331852)
3. E.A. Platz, E.B. Rimm, W.C. Willett, P.W. Kantoff, and E. Giovannucci Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals J Natl Cancer Inst 92 2000 2009 2017 (Pubitemid 32045897)
4. G.D. Steinberg, B.S. Carter, T.H. Beaty, B. Childs, and P.C. Walsh Family history and the risk of prostate cancer Prostate 17 1990 337 347
5. S.G. Roberts, M.L. Blute, E.J. Bergstralh, J.M. Slezak, and H. Zincke PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer Mayo Clin Proc 76 2001 576 581
6. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials J Clin Oncol 18 2000 3240 3246
7. L.N. Thomas, C.B. Lazier, and R. Gupta Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer Prostate 63 2005 231 239 (Pubitemid 40571057)
8. R.B. Montgomery, E.A. Mostaghel, and R. Vessella Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447 4454
9. M. Stanbrough, G.J. Bubley, and K. Ross Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815 2825
10. M.A. Titus, C.W. Gregory, O.H. Ford III, M.J. Schell, S.J. Maygarden, and J.L. Mohler Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer Clin Cancer Res 11 2005 4365 4371 (Pubitemid 40825625)
11. O. Cussenot, A.R. Azzouzi, and N. Nicolaiew Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens J Clin Oncol 25 2007 3596 3602 (Pubitemid 47376605)
12. N. Mononen, and J. Schleutker Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer J Urol 181 2009 1541 1549
13. J.Y. Park, J.P. Tanner, and T.A. Sellers Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk Urology 70 2007 374 379 (Pubitemid 47362236)
14. S.R. Setlur, C.X. Chen, and R.R. Hossain Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer Cancer Epidemiol Biomarkers Prev 19 2010 229 239
15. O. Cussenot, A.-R. Azzouzi, and N. Nicolaiew Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors Eur Urol 52 2007 1082 1089 (Pubitemid 47337033)
16. M.T. Salam, G. Ursin, E.C. Skinner, T. Dessissa, and J.K. Reichardt Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer Urol Oncol 23 2005 246 253 (Pubitemid 40961936)
17. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
18. M. Stephens, N.J. Smith, and P. Donnelly A new statistical method for haplotype reconstruction from population data Am J Hum Genet 68 2001 978 989 (Pubitemid 32289743)
19. C.L. Amling, E.J. Bergstralh, M.L. Blute, J.M. Slezak, and H. Zincke Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165 2001 1146 1151 (Pubitemid 32210224)
20. M.E. Nielsen, and A.W. Partin The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer Rev Urol 9 2007 57 62
21. J.D. Storey, and R. Tibshirani Statistical significance for genomewide studies Proc Natl Acad Sci U S A 100 2003 9440 9445 (Pubitemid 37033947)
22. T. Therneau, and P. Grambsch Modeling survival data: extending the Cox model 2000 Springer New York, NY
23. G.P. Swanson, C. Yu, M.W. Kattan, and M.R. Hermans Validation of postoperative nomograms in prostate cancer patients with long-term follow-up Urology 78 2011 105 109
24. M.S. Cicek, D.V. Conti, and A. Curran Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR Prostate 59 2004 69 76 (Pubitemid 38387844)
25. J. Li, R.J. Coates, M. Gwinn, and M.J. Khoury Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review Am J Epidemiol 171 2010 1 13
26. C. Neslund-Dudas, C.H. Bock, and K. Monaghan SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness Prostate 67 2007 1654 1663 (Pubitemid 350036951)
27. A. Shibata, M.I. Garcia, and I. Cheng Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis Prostate 52 2002 269 278
28. C.L. Pearce, D.J. Van Den Berg, and N. Makridakis No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned Hum Mol Genet 17 2008 2456 2461
29. W.P. Harris, E.A. Mostaghel, P.S. Nelson, and B. Montgomery Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion Nat Clin Pract Urol 6 2009 76 85
30. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224 (Pubitemid 36859473)
31. J. Jiang, N.L. Tang, and C. Ohlsson Association of SRD5A2 variants and serum androstane-3alpha, 17beta-diol glucuronide concentration in Chinese elderly men Clin Chem 56 2010 1742 1749